Walleye Capital
TVTX icon

Walleye Capital’s Travere Therapeutics TVTX Stock Holding History

Walleye Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Sell
3,500
-3,200
-48% -$95.7K ﹤0.01% 3655
2025
Q4 		$256K Sell
6,700
-2,000
-23% -$65K ﹤0.01% 3407
2025
Q3 		$208K Buy
+8,700
New +$164K ﹤0.01% 3294
2024
Q2 		– Sell
-1,400
Closed -$10.8K – 6024
2024
Q1 		$10.8K Buy
+1,400
New +$11.8K ﹤0.01% 5056
2023
Q4 		– Sell
-2,700
Closed -$24.1K – 5540
2023
Q3 		$24.1K Buy
+2,700
New +$38.1K ﹤0.01% 4355

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's TVTX Position: Q1 2026 in Review

Walleye Capital reduced its Travere Therapeutics (TVTX) stake by 93% in Q1 2026, selling an estimated $151K and leaving 402 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4133.

Walleye Capital first reported a position in TVTX in Q3 2019 and has held it in 21 quarters since. The position peaked at $11.3M in Q2 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Walleye Capital held 402 shares of Travere Therapeutics worth $11.9K as of Q1 2026.
  • Walleye Capital sold 5,052 Travere Therapeutics shares in Q1 2026, an estimated $151K.
  • Travere Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4133 holding.
  • Walleye Capital first reported a position in Travere Therapeutics in Q3 2019 and has held it in 21 quarters since.
  • Walleye Capital's Travere Therapeutics position peaked at $11.3M in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.